TYRA News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

TY

Mkt Cap

$1.31B

Volume

473.61K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAPomerantz LLP is investigating potential securities fraud claims against Tyra Biosciences following the company's announcement of Phase 2 study results for dabogratinib. Despite claims of a favorable safety profile, the trial showed Grade 3 adverse events in 9-14% of participants, leading to a 17.66% stock price decline on September 9, 2026.GlobeNewswire Inc. · Oct 13, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAPomerantz LLP is investigating potential securities fraud claims against Tyra Biosciences following the company's announcement of Phase 2 SURF302 study results for oral dabogratinib. Despite claims of a favorable safety profile, the study showed 14% and 9% of participants experienced Grade 3 adverse events in the 60mg and 50mg dose cohorts respectively. The announcement triggered a 17.66% stock price decline on September 9, 2026.GlobeNewswire Inc. · Oct 6, 2026

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026Boone Capital Management liquidated its entire $13.57 million stake in Cogent Biosciences (945,042 shares) in Q4 2026, despite the stock surging 372% over the past year. The fund reallocated capital to earlier-stage biotech opportunities like TYRA, which has gained 40% in 2026, suggesting a strategic shift toward higher-risk, higher-upside clinical-stage investments.The Motley Fool · Mar 20, 2026

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million StakeCommodore Capital completely exited its 3.2 million share position in Viridian Therapeutics (worth $69 million) on February 17, 2026, reducing the holding from 3.4% of the fund's assets to zero. This comes despite Viridian's stock being up 75% over the past year and entering a catalyst-heavy 2026 with FDA approval decisions and Phase 3 data expected. The exit suggests the fund may be taking profits after the strong rally or reallocating capital to other clinical-stage biotech names.The Motley Fool · Feb 23, 2026

BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsightBALVERSA (erdafitinib), a targeted therapy for FGFR-altered urothelial carcinoma, has strong market potential as precision oncology gains emphasis. Its uptake is expected to increase, especially if expanded to earlier treatment lines or additional FGFR-driven tumors.GlobeNewswire Inc. · Mar 4, 2025

Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsightThe advanced urothelial carcinoma market is witnessing significant growth, driven by an aging population and the rising prevalence of metastatic cases. Advances in immunotherapy and targeted treatments are transforming the treatment landscape, with over 20 key companies developing new therapies.GlobeNewswire Inc. · Mar 3, 2025

Tyra Biosciences hits 52-week high, reaching $21.67 By Investing.com - Investing.com AustraliaTyra Biosciences, a leading biotechnology company, has reached a new 52-week high of $21.67, reflecting its robust performance and investor confidence. The company has made progress in the development of its therapeutic candidate TYRA-300 for hypochondroplasia, with positive preclinical data presented at a research conference.Investing.com · Jul 23, 2024

Tyra Biosciences (TYRA) Upgraded to Buy: What Does It Mean for the Stock?Tyra Biosciences (TYRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.Zacks Investment Research · Jun 7, 2024

Wall Street Analysts See a 27.27% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?The consensus price target hints at a 27.3% upside potential for Tyra Biosciences (TYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.Zacks Investment Research · Jun 7, 2024

S&P 500 Gains Over 1%; Amazon Earnings Top ExpectationsU.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 1.8% on Friday. The Dow traded up 0.49% to 38,705.29 while the NASDAQ rose 1.81% to 15,639.81. The S&P 500 also rose, gaining, 1.20% to 4,965.03. Check This Out: Amazon To Rally Over 41%? Here Are 10 Top Analyst Forecasts For Friday Leading and Lagging Sectors Communication services shares rose by 4.1% on Friday. In trading on Friday, real estate shares fell by 1.9%. Top Headline Amazon.com, Inc. (NASDAQ: AMZN) posted stronger-than-expected results for its fourth quarter. The company said it sees first-quarter revenue to be between $138 billion and $143.5 billion versus estimates of $142.13 billion. Operating income is expected to be between $8 billion and $12 billion in the first quarter. Equities Trading UP Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares shot up 101% to $4.84. Intelligent Bio Solutions said it sees preliminary second-quarter revenue of $0.76 million. Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA) got a boost, surging 24% to $16.19. Tyra ...Benzinga · Feb 2, 2024

TY

TYRATyra Biosciences, Inc. Common Stock

TYRA

Pay with—

Available Balance0.00

Your PositionYou don't own any TYRA yet.

Related Tickers

Earnings